FDA Panel Votes to Expand BPC-157 Access | Sacramento News

An FDA advisory panel just voted 8 to 6 to let compounding pharmacies produce BPC-157, a peptide touted online for healing and anti-inflammation, despite limited scientific proof. Doctors, chemists, and business owners pushed for broader access, citing patient stories, while some scientists warned of safety risks. The move follows the FDA’s previous ban on 20 peptides, but this vote opens the door for prescription availability — even though official approval isn’t granted. With demand soaring and products sold on the gray market with wild claims, the debate rages on: anecdotal success vs. rigorous science — and some panelists have ties to the very industry they’re now helping. Listen in comfort:Get a discount on a Soli Pillow: http://solipillow.com/discount/dnn. Advertise on DNN:[email protected] This is an automated, high-level news summary based on public reporting.Report issues to [email protected]. View sources & latest updates:https://sources.thednn.ai/71167e190fed6e9e